Items Tagged ‘ACP-196’

December 17, 2015

ACP-196 Bruton’s Tyrosine Kinase Inhibitor Safe and Effective for Chronic Lymphocytic Leukemia


Clinical results published in the New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) is well tolerated and yields high response rates that are durable in patients with chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- […]

View full entry

Tags: Acalabrutinib, ACP-196, Chronic, Chronic Lymphocytic Leukemia, CLL, Leukemia, News